当前位置: 首页 > 期刊 > 《中国现代医生》 > 2019年第36期
编号:13432069
碳青霉烯类耐药肺炎克雷伯杆菌耐药机制及治疗策略研究进展(7)
http://www.100md.com 2019年12月25日 《中国现代医生》 2019年第36期
     [40] Jiang Y,Shen P,Wei Z,et al. Dissemination of a clone carrying a fosA3-harbouring plasmid mediates high fosfomycin resistance rate of KPC-producing Klebsiella pneumoniae in China[J]. International Journal of Antimicrob Agents,2015,45(1):66-70.

    [41] Tzouvelekis LS,Markogiannakis A,Psichogiou M,et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae:An evolving crisis of global dimensions[J]. Clin Microbiol Rev,2012,25(4):682-707.

    [42] Shields RK,Clancy CJ,Press EG,et al. Aminoglycosides for treatment of bacteremiadue to carbapenem resistant Klebsiella pneumoniae[J]. Antimicrob Agents Chemother,2016,60(5):3187-3192.

    [43] Bremmer DN,Clancy CJ,Press EG,et al. KPC-producing Klebsiella pneumoniae strains that harbor AAC(6')-Ib exhibit intermediate resistance to amikacin[J]. Antimicrob Agents Chemother,2014,58(12):7597-7600.

    [44] Li J,Bi W,Dong G,et al. The new perspective of old antibiotic:In vitro antibacterial activity of TMP-SMZ against Klebsiella pneumoniae[J]. J Microbiol Immunol Infect,2019.DOI:10.1016/j.jmii.2018,12.013.

    [45] Nq SMS,Sioson JSP,Yap JM,et al. Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections[J]. Eur J Clin Microbiol Infect Dis,2018,37(1):141-148.

    (收稿日期:2019-09-03), 百拇医药(赖宁燕 虞亦鸣 邓在春)
上一页1 2 3 4 5 6 7